• Molecular NameClofarabine
  • Synonymclofarabine
  • Weight303.681
  • Drugbank_IDDB00631
  • ACS_NO123318-82-1
  • Show 3D model
  • LogP (experiment)-0.151
  • LogP (predicted, AB/LogP v2.0)-0.3
  • pkaN/A
  • LogD (pH=7, predicted)-0.3
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.21
  • LogSw (predicted, AB/LogsW2.0)39.61
  • Sw (mg/ml) (predicted, ACD/Labs)18.81
  • No.of HBond Donors4
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds2
  • TPSA119.31
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA purine nucleoside antimetabolite
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability50.0
  • Protein binding47.0
  • Volume of distribution (VD)172
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmClofarabine is sequentially metabolized intracellularly to the 5’-monophosphate metabolite by deoxycytidine kinase and mono- and di-phosphokinases to the active 5’-triphosphate metabolite. Clofarabine has high affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equal to or greater than that of the natural substrate, deoxycytidine.
  • Half lifeThe terminal half-life is estimated to be 5.2 hours.
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A